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An Insight into the Global Burden of
Skin Diseases
Loes M. Hollestein1 and Tamar Nijsten1
The skin conditions expert group of the Global Burden of Disease 2010 study
estimated the global burden of skin conditions worldwide. Health loss due to 15
skin diseases between 1990 and 2010 for 187 countries was quantified. All skin
conditions combined were the fourth leading cause of non-fatal disease burden at
the global level. The burden of skin conditions was high in both high- and low-
income countries, indicating that prevention of skin diseases should be prioritized.
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The Global Burden of Disease (GBD)
2010 study
The results of the Global Burden of
Disease 2010 (GBD 2010) study, a
collaborative effort by 486 scientist
from 50 countries, have been pub-
lished in the Lancet in December
2012. The goal of the GBD 2010 study
is to provide an evidence-based assess-
ment and ranking of people’s health
problems around the world. The GBD
estimates are important for developing
population health policies, health care
planning and allocation of research
funding. The challenge in this effort is
to agree upon a common denominator
that allows for comparisons between
diseases. The impact of a disease on
the patient and societal level is a
combination of its prevalence, its mor-
bidity and mortality, the impact on
patient’s lives, available treatments
and associated costs. To compare
health loss across different diseases
the Disability Adjusted Life Year
(DALY) was developed. This measure
describes the fatal as well as the non-
fatal health loss (i.e., Years of Life lived
with Disability (YLD) þYears of Life
Lost (YLL)(Table 1). For the DALY
calculation, the disability weights for
each disease needs to be assessed. The
GBD 2010 study identified 1160
sequelae of 289 diseases and injuries,
which were subsequently reduced to
220 unique health states. People from
the general population were asked to
compare brief lay descriptions of these
See related article on pg 1527 health states, from which new disability
weights were calculated (Murray et al.,
2012). In this issue of the Journal of
Investigative Dermatology, an expert
group focused on the global burden of
skin conditions (Hay et al., 2014).
Global burden of skin conditions
The methodology to answer a relatively
simple question ‘‘what is the global
burden of a specific skin disease’’ is
highly complex (Figure 1). First, a sys-
tematic review to collect epidemiologi-
cal data on 15 common skin diseases
was performed. To harmonize discor-
dant data and fill in possible gaps,
DISMOD-MR was used to provide esti-
mates of prevalence and mortality
worldwide for all skin conditions.
Table 1. Abbreviations and descriptions of concepts used in the Global
Burden of Disease 2010 study (Salomon et al., 2012)
AbbreviationConcept Description
Disability Disability refers to any short-term or long-term health loss.
Sequelae In the GBD 2010 list, there are 291 diseases and injuries, of which
289 cause disability. In total, 1,160 sequelae of these diseases and
injuries have been identified.
Example: viral warts is a sequela of viral skin diseases.
Health state Across the 1,160 sequelae, 220 unique health states have been
identified. The list of unique health states serves two purposes: to
allow assessment of the total burden of some health states such as
disfigurement across various causes and to simplify the task of
measuring disability weights for sequelae.
Example: disfigurement level 1 with itch/pain is an unique health
state, which can be a consequence of eczema, psoriasis, and
cellulitus, as well as urticaria.
Disability weight A quantification of the severity of health loss associated with the
220 health states on a scale from 0 to 1, where 0 represents perfect
health and 1 represents death.
Example: the health state ‘‘disfigurement level 1’’ has the disability
weight 0.013.
Interpretation: on average, society prefers a person to live 3 years
with disfigurement level 1 (3 years 0.013¼0.039) than 1 year
with disfigurement level 3 (1 year0.398¼ 0.398).
YLD Years of life lived
with disability
Non-fatal health loss: YLD represents the years of life lived in less
than ideal health.
Calculation: number of prevalent cases disability
weight average duration of the disease until remission or death.
YLL Years of life lost Fatal health loss: YLL represents the lost life years in a population,
because of premature mortality.
Calculation: number of deaths standard life expectancy at age of
death in years.
DALY Disability adjusted
life years
One DALY can be interpreted as the loss of one year of life lived in
full health.
Calculation: YLDþYLL.
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The findings confirmed the impor-
tance of dermatology on a regional
and a global level. Fungal diseases, acne
vulgaris and other skin diseases com-
bined were in the top-10 of most pre-
valent diseases. All skin conditions
combined were fourth leading cause of
non-fatal disease burden on a global
level. Other key findings were that
skin infections accounted for a large
proportion of YLD in tropical and
resource-poor regions, whereas eczema
accounted for a large part of YLD in all
regions. Across age groups, eczema
put a heavy burden on children, acne
on teenagers and a mix of eczema,
ulceration, non-melanoma skin cancer
(NMSC), infections and pruritus on the
elderly.
Selection of 15 common skin conditions
The selection of skin conditions reflects
the prevalence, the case definition and
the availability of the data. This list may
be more in line with skin diseases
treated by general practitioners (GP)
than the daily practice of most derma-
tologists (especially in countries where
the GP is the first point of medical
contact for persons with skin condi-
tions). Some of the frequently seen con-
ditions in dermatological practices such
as melanoma, benign skin tumors, and
varicose veins and its complications
are missing, because they have been
classified elsewhere in the GBD 2010
study. For example, 13% of all visits
to a dermatologist in the Netherlands
is related to varicose veins and 7% to
benign skin tumors (De Vries, 2013).
In the United Kingdom, approximately
one third of all GP consults related to
skin conditions were classified elsewhere
in the International Classification of
Disease (ICD)-9 (rather than chapter 12
‘‘Diseases of the skin and subcutaneous
tissue’’), indicating that these missing
skin conditions in the current analyses
lead to a substantial underestimation of
the true burden attributable to skin
conditions (Schofield et al., 2011).
The category ‘‘other skin diseases’’
included skin conditions which are less
frequent or lacked data availability. This
combination category also includes skin
conditions with high individual burden,
Clinical Implications
 Skin conditions put a large burden on health care systems worldwide.
 Prevention of skin conditions should be prioritized.
 Highly prevalent skin conditions with a small individual burden may lead
to a high burden on a population level.
Selection of 15 skin diseases:
-  EczemaExcluded:
MethodologyResults
Selection of 15 skin diseases (ICD-10)
(based on prevalence, case definition, data availability)
Systematic review (1980–2010)
(Medline, Embase, surveys, unpublished data)
Data:
Prevalence and mortality:
YLD and DALY:
• 895 Country-years
• 82 Countries
• 3 Diseases in top 10 prevalence:
• 8 Diseases in top 50 prevalence
• Annual mortality: >100,000
• Large regional differences
• Global YLD rank: 4th (country
 level: 2nd–11th)
• Global DALY rank: 18th (country
 level: 3rd–28th)
• Females > males
• Age peak: 15 years
• Increases with age
• Large regional differences
• Annual percentage change
 differs per region
- Fungal disease
- Acne vulgaris
- Other skin conditions
Disease estimates: Study characteristics:
Statistical modeling: DisMod-MR
(negative binomial Bayesian meta-regression (MR) tool)
Prevalence and mortality estimates
YLD (non-fatal health loss)
YLL (fatal health loss)
DALY (fatal and non-fatal health loss)
-  Incidence
-  Prevalence
-  Age and gender
-  Severity distribution
-  Country
-  Sample size
-  Time period
-  Remission
-  Mortality
-  N <100
-  Self-reported
-  Specific populations
-  Non-random samples
-  Experimental arm clinical trial
-  Estimates without actual data
Study level covariates for predictions:
-  Case definition
-  In/outpatient
-  Country-level covariates:
-  Access to health care
-  Mean temperature
-  % Access to sanitation
-  Melanoma incidence
-  19 Sequelae of skin disease
-  10 Unique health states
-  Disability weights re-estimated
 using surveys
-  Disease duration and severity
 estimated by experts
-  Mean sugar intake
-  Psoriasis
-  Acne vulgaris
-  Pruritus
-  Alopecia areata
-  Decubitus ulcer
-  Urticaria
-  Scabies
-  Fungal skin diseases
-  Impetigo
-  Cellulitus
-  Viral warts
-  Molluscum contagiosum
-  Non-melanoma skin cancer
-  Abscess and other bacterial
  skin diseases
-  Other skin conditions
Figure 1. Methodology and Results of the Global Burden of Skin Disease Study 2010. DALY, disability adjusted life years; ICD, International Classification of
Diseases; N, number; YLD, years of life lived with disability; YLL, years of life lost.
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such as bulleous diseases, connective
tissue diseases and severe cutaneous
drug reactions. This category was
assigned the health state ‘‘disfigurement
level 1,’’ which has the disability weight
0.013 indicating that the true loss of
YLD in the population is even higher.
Functional health loss and psychological
impact of skin conditions
In the GBD 2010 study, the disability
weights of the 220 unique health states
were re-estimated using face-to-face or
telephone surveys among 13,000 indi-
viduals in five different countries and an
open-access web-based survey among
16,000 individuals (Salomon et al.,
2012). This is a huge improvement
compared to the previous ‘‘one size,
fits all’’ disability weight of 0.056,
which was estimated by a small panel
of health experts (World Health Organi-
zation, 2004). In the GBD 2010 study,
seven different weights (ranging from
0.013 to 0.562, excluding skin cancer),
which were depend on disease severity,
were included. The current disability
weights quantify functional health loss
to make a clear distinction between
health and wellbeing. Although this
approach was chosen to explicitly
quantify health loss rather than welfare
loss, the exclusion of the psychological
burden leads to an underestimation of
the true non-fatal burden in the popula-
tion. This underestimation is especially
true for skin conditions because the
psychological burden of skin diseases
can be substantial (Ahmed et al.,
2013). Also, the reduction of 1,160
sequelae to 220 unique health states
was needed to for feasibility reasons,
but may have led to an oversimpli-
fication. For example, melanoma and
NMSC were assigned the same disabi-
lity weights as well as all other cancers,
while the psychological impact is likely
to be very different.
Individual burden versus population
burden
The estimation of the YLD of a disease
depends on the prevalence and the
severity of a disease. Many of the
selected skin conditions have a relatively
mild impact on patient’s lives in the
majority of all patients, such as eczema
and acne vulgaris. However, due to the
very high prevalence of these skin dis-
eases, the burden (YLD) on a population
level is enormous. From a public health
perspective, these diseases are of interest
because they represent a high YLD, but
many clinicians may argue that a focus
on disease with a higher individual
disease burden, but low YLD, require
more attention (e.g., bulleous diseases,
connective tissue diseases and severe
cutaneous drug reactions). This potential
conflict between population and indivi-
dual perspective, and thus prioritization,
is in line with what is often seen in cost-
effectiveness evaluations of health care
interventions. As a society we should
answer the question if we would we like
to treat many people who can cope with
their skin condition or if we would like
to treat a small number of people who
experience a high disability due to their
skin disease?
Conclusion
What physicians who treat patients with
skin diseases have known for a long time
(i.e., ‘‘you hardly ever die from a skin
disease, but it can be truly bothersome’’)
has now been empirically confirmed:
skin diseases are an important cause of
health loss on a global level. The find-
ings of this beautiful study stimulates
researchers to further assess and refine
the specific impact of skin diseases in
order to monitor (reductions) of health
loss due to skin conditions in the future.
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22 Again: IL-22 as a Risk Gene and
Important Mediator in Psoriasis
Andrew Johnston1 and Johann E. Gudjonsson1
IL-22 targets our external epithelial barriers, bolstering our defenses, and has long
been implicated in the pathogenesis of psoriasis. Nikamo and colleagues (2014)
identify a haplotype in the IL22 promoter with a strong association to juvenile-onset
psoriasis and demonstrate that this risk variant is associated with increased IL-22
production by T cells. We explore the implications of this work.
Journal of Investigative Dermatology (2014) 134, 1501–1503; doi:10.1038/jid.2014.81
IL-22 is a cytokine that targets our
external epithelial barriers such as those
of the lungs, gastrointestinal (GI) tract,
and the skin, bolstering our defenses
against external insults. Moreover,
IL-22 has long been implicated in the
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